News | Chronic Total Occlusion (CTO) | May 14, 2018

International Registry Shows Good Outcomes in Treating Chronic Total Occlusions (CTOs)

The hybrid approach of PCI for CTO occlusion in more than 3,000 patients — an update from the PROspective Global Registry for the Study of Chronic Total Occlusion Intervention) International Registry

PROGRESS-CTO flow chart for the hybrid algorithm. #SCAI, #SCAI2018

May 14, 2018 — A significant update to the PROGRESS-CTO (PROspective Global Registry for the Study of Chronic Total Occlusion Intervention) International Registry was presented as late-breaking clinical science at 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. The study includes results of Chronic Total Occlusion Percutaneous Intervention (CTO PCI) for more than 3,000 patients across 20 centers in the United States, Europe, and Russia. The new data from the PROGRESS-CTO registry are representative of contemporary practice and outcomes.

The World Health Organization (WHO) estimates that 7.3 million deaths around the world are due to coronary heart disease making it the second cause of death in people under the age of 59 after HIV/AIDS, and reaching the first position in those 60 years and older.[1] Approximately 20 percent of such patients are known to have a complication from CAD called CTO, or complete blockages of the arteries that have typically been present for more than three months.[2] CTO PCI is a minimally invasive procedure that has been evolving with constant improvement of equipment and techniques.

The authors outline contemporary outcomes of CTO PCI by analyzing the clinical, angiographic and procedural characteristics of 3,122 CTO interventions performed in 3,055 patients at 20 centers in the United States (17), Europe (2) and Russia (1). The researchers analyzed success rates of antegrade wire escalation, antegrade dissection and re-entry and the retrograde approach on CTO interventions performed.

The mean age was 65 (plus or minus 10 years) and 85 percent of the patients were men with high prevalence of diabetes (43 percent), prior myocardial infarction (MI) (46 percent), prior coronary artery bypass graft surgery (33 percent) and prior PCI (65 percent). The overall technical and procedural success rate was 87 percent and 85 percent, respectively. The rate of in-hospital major complications was 3 percent (composite of death 0.9 percent), acute MI (1.1 percent), stroke (0.3 percent), tamponade (0.9 percent), emergency surgery (0.2 percent) and re-PCI (0.4 percent). The success rates for the antegrade wire escalation, antegrade dissection and re-entry and retrograde approach were 87.3 percent, 89.7 percent and 83 percent, respectively.

“The high success and acceptable complication rates suggest that at experienced centers CTO PCI can provide significant clinical benefits to the patients,” said Peter Tajti, M.D., Abbott Northwestern Hospital, Minneapolis Heart Institute. “The study results can facilitate discussions with both patients and physicians about the risk to benefits of the procedure and guide decision making on CTO PCI.”

The authors are working on a new, multi-center study including centers from around the world to further assess the effect of CTO PCI symptoms when compared to the placebo-controlled procedure.

This study is published online by JACC: Cardiovascular Interventions.[3]

 

Complete listing of SCAI 2018 late-breaking trials with links to articles.

 

Read more on CTO Therapies:

VIDEO: New Technology to Treat Chronic Total Occlusions (CTOs) — interview with Farouc Jaffer, M.D., Ph.D., director of coronary interventions at Massachusetts General Hospital

How to Tackle Coronary CTOs

VIDEO: Treating Chronic Total Occlusions — interview with Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington

 

References:

1. Gemma Vilahur, Juan José Badimon, Raffaele Bugiardini and Lina Badimon. Perspectives: The burden of cardiovascular risk factors and coronary heart disease in Europe and worldwide. European Heart Journal Supplements, Volume 16, Issue suppl_A, 1 January 2014, Pages A7–A11, https://doi.org/10.1093/eurheartj/sut003

2. Azzalini L, Jolicoeur EM, Pighi M, Millán X,et al. Epidemiology, Management Strategies, and Outcomes of Patients With Chronic Total Coronary Occlusion. Am J Cardiol. 2016 Oct 15;118(8):1128-1135. doi: 10.1016/j.amjcard.2016.07.023. Epub 2016 Jul 28. https://www.ncbi.nlm.nih.gov/pubmed/27561190

3. Peter Tajti, Dimitri Karmpaliotis, Khaldoon Alaswad,et al. The Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention. Update From the PROGRESS CTO Registry. JACC: Cardiovascular Interventions. April 2018. DOI: 10.1016/j.jcin.2018.02.036

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init